Dyspareunia Treatment Market, By Drug Type (Selective Estrogen Receptor Modulators, Estrogens, Corticosteroids, Antibiotics, and Others), By Route of Administration, By Distribution Channel, By Geography

Description

The dyspareunia treatment market is estimated to be valued at USD 754.1 Mn in 2024 and is expected to reach USD 1,035.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 754.1 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.60%	2031 Value Projection:	US$ 1,035.4 Mn

Figure. Dyspareunia Treatment Market Share (%), By Region 2024

Dyspareunia, or painful sexual intercourse, is a prevalent issue that affects women globally. It is characterized by pain in the pelvic region or surrounding area during or after penetration, and has physical as well as psychological implications. The exact causes may vary from person to person, but common contributors include vaginal infections, endometriosis, psychological factors, and pelvic area injuries during childbirth. If left untreated, it can have a negative impact on quality of life and sexual relationships. The dyspareunia treatment market consists of pharmaceutical and medical device options that provide relief from pain and help restore intimacy. Advancements in therapeutic areas like hormonal therapy, physical therapy, and minimally invasive procedures are expanding choices for managing this condition effectively.

Market Dynamics:

Rising awareness about available treatment choices and more open discussion of female sexuality are driving the dyspareunia treatment market. Historical stigma around women's health issues is gradually reducing as patients feel more empowered to seek care. Growing demand for non-invasive and non-drug alternatives to pharmacological management is opening up opportunities for physical therapy tools and medical devices in this space. However, high costs associated with newer technologies could restrict market expansion to some degree. Cultural and social barriers continue to hamper help-seeking behavior in certain regions as well. Meanwhile, an aging population presenting with pelvic floor disorders and neurological issues presents new prospects for market participants.

Key Features of the Study:

This report provides an in-depth analysis of the global dyspareunia treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dyspareunia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD, Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd., Cosette Pharmaceuticals, Inc., and Mundipharma International
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dyspareunia treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dyspareunia treatment market

Detailed Segmentation-

Drug Type:
- Selective Estrogen Receptor Modulators
- Estrogens (Miscellaneous Vaginal Agents)
- Corticosteroids
- Antibiotics
- Others
Route of Administration:
- Oral
- Vaginal Inserts
- Others
Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- E-Commerce
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Lupin
- Pfizer Inc.
- AbbVie Inc.
- Duchesnay Inc.
- AMAG Pharmaceuticals, Inc.
- Amneal Pharmaceuticals LLC.
- TherapeuticsMD, Inc.
- Sumitomo Pharma Co., Ltd.,
- Myovant Sciences
- Novo Nordisk A/S
- Viatris Inc.
- Shionogi & Co., Ltd.
- Millicent Pharma Ltd.
- Cosette Pharmaceuticals, Inc.
- Mundipharma International

Product Code: CMI6885

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Fundings and Investments
Reimbursement Scenario
PEST Analysis
Porter's Analysis

4. Global Dyspareunia Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Dyspareunia Treatment Market, By Drug Type, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Selective Estrogen Receptor Modulators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Estrogens (Miscellaneous Vaginal Agents)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Dyspareunia Treatment Market, By Route of Administration, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Vaginal Inserts
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Dyspareunia Treatment Market, By Distribution Channel, 2019 - 2031, (USD Mn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
E-commerce
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Dyspareunia Treatment Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Lupin*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Duchesnay Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AMAG Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amneal Pharmaceuticals LLC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- TherapeuticsMD, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sumitomo Pharma Co., Ltd.,
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Myovant Sciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Shionogi & Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Millicent Pharma Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Cosette Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Mundipharma International
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact